Autophagy in Paediatric Crohn's Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Blood samples: Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
Biopsies: 5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
Study summary
Crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. Indeed, GWAS (Genome-Wide Association Studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. Among them genes coding for proteins involved in autophagy machinery (i.e: ATG16L1, IRGM et NDP52). Autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling.
So far, the role of autophagy in gut inflammation and intestinal homeostasis in Crohn's disease patients is partially understand. Then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a Crohn's disease compare to controls.
Eligibility
Primary outcome measure(s)
- Quantification of autophagic flux by western blot. — 1 day (during hospitalization for ileocolonoscopy)
LC3II/LC3I will be measured by western blot after booking the autophagic flux at different time point.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service Hépatologie, Gastroentérologie et Nutrition pédiatrique, Hôpital Femme Mère Enfant, HCL | Bron | France |
More Hospices Civils de Lyon trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05842564 on ClinicalTrials.gov ↗ ← All trials in France